These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30157803)

  • 41. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study.
    Kaye SB; Mead GM; Fossa S; Cullen M; deWit R; Bodrogi I; van Groeningen C; Sylvester R; Collette L; Stenning S; De Prijck L; Lallemand E; deMulder P
    J Clin Oncol; 1998 Feb; 16(2):692-701. PubMed ID: 9469359
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment in germ cell tumours: state of the art.
    Tjan-Heijnen VC; Oosterhof GO; de Wit R; De Mulder PH
    Eur J Surg Oncol; 1997 Apr; 23(2):110-7. PubMed ID: 9158183
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Administration of standard-dose BEP regimen (bleomycin+etoposide+cisplatin) is essential for treatment of ovarian yolk sac tumour.
    Satoh T; Aoki Y; Kasamatsu T; Ochiai K; Takano M; Watanabe Y; Kikkawa F; Takeshima N; Hatae M; Yokota H; Saito T; Yaegashi N; Kobayashi H; Baba T; Kodama S; Saito T; Sakuragi N; Sumi T; Kamura T; Yoshikawa H
    Eur J Cancer; 2015 Feb; 51(3):340-51. PubMed ID: 25559616
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial.
    Culine S; Theodore C; Terrier-Lacombe MJ; Droz JP
    J Urol; 1997 Mar; 157(3):855-8; discussion 858-9. PubMed ID: 9072585
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.
    Tandstad T; Dahl O; Cohn-Cedermark G; Cavallin-Stahl E; Stierner U; Solberg A; Langberg C; Bremnes RM; Laurell A; Wijkstrøm H; Klepp O
    J Clin Oncol; 2009 May; 27(13):2122-8. PubMed ID: 19307506
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Renal impairment and late toxicity in germ-cell cancer survivors.
    Lauritsen J; Mortensen MS; Kier MGG; Christensen IJ; Agerbaek M; Gupta R; Daugaard G
    Ann Oncol; 2015 Jan; 26(1):173-178. PubMed ID: 25361985
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial.
    Mead GM; Cullen MH; Huddart R; Harper P; Rustin GJ; Cook PA; Stenning SP; Mason M;
    Br J Cancer; 2005 Jul; 93(2):178-84. PubMed ID: 15999102
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The management of poor-prognosis, non-seminomatous germ-cell tumours.
    Sirohi B; Huddart R
    Clin Oncol (R Coll Radiol); 2005 Oct; 17(7):543-52. PubMed ID: 16238142
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [BEP/VIP in children and adolescents with malignant non-testicular germ cell tumors. A comparison of the results of treatment of therapy studies MAKEI 83/86 and 89P/89].
    Göbel U; Calaminus G; Teske C; Bamberg M; Bökkerink JP; Haas RJ; Holschneider AM; Janka-Schaub G; Jürgens H; Mittler U
    Klin Padiatr; 1993; 205(4):231-40. PubMed ID: 7690864
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial.
    Grimison PS; Stockler MR; Thomson DB; Olver IN; Harvey VJ; Gebski VJ; Lewis CR; Levi JA; Boyer MJ; Gurney H; Craft P; Boland AL; Simes RJ; Toner GC
    J Natl Cancer Inst; 2010 Aug; 102(16):1253-62. PubMed ID: 20631341
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Modified-BEP Chemotherapy in Patients With Germ-Cell Tumors Treated at a Comprehensive Cancer Center.
    Aurilio G; Verri E; Frassoni S; Bagnardi V; Cossu Rocca M; Cullurà D; Milani M; Mascia R; Curigliano G; Orsi F; Jereczek-Fossa BA; Musi G; Omodeo Salè E; De Cobelli O; Nolè F
    Am J Clin Oncol; 2020 Jun; 43(6):381-387. PubMed ID: 32079853
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Therapeutic evaluation of cisplatin, etoposide, and bleomycin chemotherapy regimen in high-risk gestational trophoblastic neoplasia].
    Song SQ; Zhang GN
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):571-6. PubMed ID: 23141175
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-Term Survival of Good-Risk Germ Cell Tumor Patients After Postchemotherapy Retroperitoneal Lymph Node Dissection: A Comparison of BEP × 3 vs. EP × 4 and Treating Institution.
    Cary C; Jacob JM; Albany C; Masterson TA; Hanna NH; Einhorn LH; Foster RS
    Clin Genitourin Cancer; 2018 Apr; 16(2):e307-e313. PubMed ID: 29104087
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom.
    Fosså SD; Kaye SB; Mead GM; Cullen M; de Wit R; Bodrogi I; van Groeningen CJ; De Mulder PH; Stenning S; Lallemand E; De Prijck L; Collette L
    J Clin Oncol; 1998 Feb; 16(2):716-24. PubMed ID: 9469362
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study.
    Nichols CR; Catalano PJ; Crawford ED; Vogelzang NJ; Einhorn LH; Loehrer PJ
    J Clin Oncol; 1998 Apr; 16(4):1287-93. PubMed ID: 9552027
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Frequency and risk factors of bleomycin-induced pulmonary toxicity in South Indian patients with germ-cell tumors.
    Thakkar DN; Ramasamy K; Adithan S; Selvarajan S; Dubashi B
    J Cancer Res Ther; 2021; 17(2):443-449. PubMed ID: 34121690
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pilot study of cisplatin, etoposide, bleomycin, and escalating dose cyclophosphamide therapy for children with high risk germ cell tumors: a report of the children's oncology group (COG).
    Malogolowkin MH; Krailo M; Marina N; Olson T; Frazier AL
    Pediatr Blood Cancer; 2013 Oct; 60(10):1602-5. PubMed ID: 23703725
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors.
    Feldman DR; Hu J; Dorff TB; Lim K; Patil S; Woo KM; Carousso M; Hughes A; Sheinfeld J; Bains M; Daneshmand S; Ketchens C; Bajorin DF; Bosl GJ; Quinn DI; Motzer RJ
    J Clin Oncol; 2016 Jul; 34(21):2478-83. PubMed ID: 27185842
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Suggested Prognostic Reclassification of Intermediate and Poor-Risk Nonseminomatous Germ Cell Tumors.
    Necchi A; Pond GR; Nicolai N; Giannatempo P; Raggi D; Adra N; Hanna NH; Salvioni R; Einhorn LH; Albany C
    Clin Genitourin Cancer; 2017 Apr; 15(2):306-312.e3. PubMed ID: 27594554
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Paclitaxel, bleomycin, etoposide, and cisplatin (T-BEP) as initial treatment in patients with poor-prognosis germ cell tumors (GCT): a phase II study.
    Mardiak J; Sálek T; Sycová-Milá Z; Obertová J; Recková M; Mego M; Hlavatá Z; Brozmanová K; Risnyovzská Z; Svetlovská D; Koza I
    Neoplasma; 2007; 54(3):240-5. PubMed ID: 17447857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.